{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:13:12Z","timestamp":1792177992923,"version":"4.4.0"},"reference-count":39,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2010,9,2]],"date-time":"2010-09-02T00:00:00Z","timestamp":1283385600000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Headache"],"published-print":{"date-parts":[[2010,9]]},"abstract":"<jats:p>\n                    <jats:bold>Objective.\u2014<\/jats:bold>\n                    To explore the efficacy and tolerability of levetiracetam in medical treatment of trigeminal neuralgia.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Background.\u2014<\/jats:bold>\n                    Antiepileptic drugs (AEDs) are considered as first\u2010line treatment for trigeminal neuralgia, although their use is often limited due to incomplete efficacy and tolerability. Newer AEDs with improved safety profile may be useful in this disorder.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods.\u2014<\/jats:bold>\n                    Patients suffering from trigeminal neuralgia (either primary or secondary) refractory to previous treatments were recruited to be treated with levetiracetam (3\u20104\u2003g\/day) for 16 weeks as add\u2010on therapy, after a 2\u2010week baseline period. Rescue medication was allowed in both the baseline and treatment phases. The primary efficacy measure was the number of attacks per day. The patients' efficacy evaluation, the patients' global evaluation for both safety and efficacy, changes in the Hamilton Depression Scale, the Hamilton Anxiety Scale, and the Quality of Life Measure Short Form\u201036 were secondary parameters.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results.\u2014<\/jats:bold>\n                    Twenty\u2010three patients were included in the analysis. After treatment and compared to the baseline phase, the number of daily attacks decreased by 62.4%. All secondary parameters changed significantly with the exception of the Quality of Life Measure Short Form\u201036 score. Seven patients withdrew from the study. Five patients (21.7%) reported side effects and 2 withdrew.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions.\u2014<\/jats:bold>\n                    Levetiracetam may be effective and safe in trigeminal neuralgia treatment. Confirmation in a randomized controlled study is needed.\n                  <\/jats:p>\n                  <jats:p>\n                    (\n                    <jats:italic>Headache<\/jats:italic>\n                    2010;50:1371\u20101377)\n                  <\/jats:p>","DOI":"10.1111\/j.1526-4610.2010.01743.x","type":"journal-article","created":{"date-parts":[[2010,9,8]],"date-time":"2010-09-08T12:41:17Z","timestamp":1283949677000},"page":"1371-1377","source":"Crossref","is-referenced-by-count":35,"title":["An Observational Trial to Investigate the Efficacy and Tolerability of Levetiracetam in Trigeminal Neuralgia"],"prefix":"10.1111","volume":"50","author":[{"given":"Dimos D.","family":"Mitsikostas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George V.","family":"Pantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore G.","family":"Avramidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klimentini E.","family":"Karageorgiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stylianos D.","family":"Gatzonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantelis G.","family":"Stathis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassiliki A.","family":"Fili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna D.","family":"Siatouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michail","family":"Vikelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,9,2]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002508-200201000-00003"},{"issue":"1","key":"e_1_2_7_3_2","first-page":"126","article-title":"Subcommittee of the International Headache Society. The International Classification Of Headache Disorders \u2013 2nd Edition","volume":"24","author":"Headache Classification","year":"2004","journal-title":"Cephalalgia"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2296-9-26"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.9.3.323"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(62)91847-0"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1977222196"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1968.00480020015001"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002508-200201000-00002"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2009.08.037"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.5.615"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.4.11.2079"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.wnf.0000159956.87511.67"},{"key":"e_1_2_7_14_2","first-page":"467","article-title":"Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial\u2010onset seizures","volume":"5","author":"Ulloa CM","year":"2009","journal-title":"Neuropsychiatr Dis Treat"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp070607"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002508-200401000-00007"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(03)01933-2"},{"issue":"3","key":"e_1_2_7_18_2","article-title":"Anticonvulsant drugs for acute and chronic pain","author":"Wiffen P","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.8.2.126"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1980.tb131854.x"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1054\/jpai.2002.122944"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2007.04.010"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006044.pub2"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.59.5_suppl_2.S14"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(01)00275-5"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2007.01483.x"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a3006"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8260.1967.tb00530.x"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1959.tb00467.x"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2001.tb05822.x"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2003.12004.x"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0173(00)00048-5"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.5.615"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2008.02496.x"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-6576.2007.01578.x"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpain.2005.03.011"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000326598.83183.04"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252941.50833.4a"},{"key":"e_1_2_7_39_2","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0090-9556(24)15285-3","article-title":"In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent","volume":"27","author":"Nicolas JM","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2006.00461.x"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1526-4610.2010.01743.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1526-4610.2010.01743.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T13:34:57Z","timestamp":1762090497000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/j.1526-4610.2010.01743.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["10.1111\/j.1526-4610.2010.01743.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1526-4610.2010.01743.x","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}